United States President Donald Trump on Monday signed an executive order instructing the Food and Drug Administration (FDA) to accelerate the approval process for domestically manufactured pharmaceuticals. The directive marks a strategic move to enhance the country’s drug supply chain resilience and reduce dependency on foreign production.

As part of the order, the FDA has also been directed to raise inspection fees for foreign drug manufacturing facilities operating within the United States. Additionally, the agency will conduct more frequent and stringent inspections of those plants. Trump emphasized the need for increased transparency, calling for pharmaceutical companies to be more forthright about the sources of their ingredients. The FDA is expected to publicly disclose facilities that fail to meet compliance standards.

The President also tasked the Environmental Protection Agency (EPA) with expediting the construction approval process for facilities focused on producing prescription drugs, active pharmaceutical ingredients, and other essential raw materials. The effort is designed to encourage domestic pharmaceutical production and decrease reliance on international suppliers.

In a separate Oval Office exchange with reporters, President Trump revealed plans to impose tariffs on imported pharmaceuticals. While he did not specify the rates or targeted countries, he stated that an official announcement would be made within the next two weeks. The measure follows speculation that the tariffs could mirror the 25% levies previously placed on automobile and aluminum imports.

These actions come amid broader efforts by the Trump administration to lower drug prices, safeguard national health security, and prioritize U.S.-based manufacturing in the wake of global supply chain vulnerabilities exposed during recent crises.